<DOC>
	<DOCNO>NCT00003956</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness SCH 66336 , fluorouracil , leucovorin treat patient advanced cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety , tolerability , maximum tolerate dose , dose limit toxicity oral SCH 66336 fluorouracil leucovorin calcium patient advanced malignancy . II . Assess multiple dose pharmacokinetics oral SCH 66336 administer fluorouracil leucovorin calcium . III . Assess pharmacokinetics fluorouracil administer oral SCH 66336 . IV . Assess antitumor activity oral SCH 66336 fluorouracil leucovorin calcium patient . OUTLINE : This dose escalation study SCH 66336 . Patients receive oral SCH 66336 twice daily 56 day . Patients receive leucovorin calcium IV 1-2 minute immediately follow fluorouracil IV 1-2 minute day 1 , 8 , 15 , 22 , 29 , 36 . Courses repeat every 56 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SCH 66336 . The maximum tolerate dose define dose 1 6 patient experience dose limit toxicity ( DLT ) course 1 , least 2 patient experience DLT next high level . PROJECTED ACCRUAL : Approximately 25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven malignancy curative therapy exist At least 1 bidimensionally measurable lesion No acute chronic leukemia multiple myeloma No active CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOGWHO 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 3 time upper limit normal ( ULN ) ( 5 time ULN elevation due liver metastasis ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No prior concurrent QTc interval prolongation great 500 m/sec , unless approve cardiology consult prior study Other : No malabsorption syndrome due surgery , prior disease , unknown reason No frequent vomit medical condition could interfere oral medicine intake ( e.g. , partial bowel obstruction , external biliary diversion ) No concurrent nonmalignant systemic disease make patient poor risk study No active uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No prior allogeneic , syngeneic , autologous bone marrow transplantation No prior peripheral blood stem cell transplantation No concurrent biologic therapy Chemotherapy : No 2 prior chemotherapy regimen At least 4 week since prior chemotherapy ( 6 week since mitomycin nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No prior wide field radiation ( radiotherapy least 25 % bone marrow , include pelvic irradiation ) No concurrent radiotherapy Surgery : Prior major gastrointestinal surgery allow recover Other : At least 4 week since prior investigational therapy recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>